Ticker: ZVSA

ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA) Quick read: clinical‑stage biotech with two programs (VAR 200 and IC 100). Management cut spending year‑over‑year, but the company is in a cash crisis, faces Nasdaq delisting, heavy vendor concentration and large potential dilution from warrants. Recent ...